EUCTR2004-005059-32-BE进行中（未招募）不适用
A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma - Not Available
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological diagnosis of malignant melanoma; Measureable unresectable Stage III or IV melanoma; at least 18 years of age; positive for HLA-A*0201; have demonstrated 1 of the following in response to at least 1 cycle of 1 or more regimens containing 1 or more of the following: IL-2, dacarbazine,temozolamide, fotomustine, and/or carboplatin: 1) relapse following an objective response 2) failed to demonstrate an objective response or 3) inability to tolerate treatment due to unacceptable toxicity; at least 28 days since treatment with chemotherapy, biochemotherapy, surgery, radiation, or immunotherapy; negative pregnancy testing; life expectancy greater than 4 months; ECOG of 0 or 1; meet required lab values; and negative HIV, HepB and HepC tests.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any other prior malignancy from which the patient has been disease free for less than 5 years (except adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast or bladder); primay ocular melanoma; active, untreated CNS metastasis; prior treatment with an anti-CTLA4 antibody; active autoimmune disease or a history of autoimmune disease except for vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism; pregnant or nursing; Hypersensitivity to Incomplete Freund's Adjuvant or component of the vaccine; any underlying condition which in the opinion of the investigator will make administration of the study drug hazardous or obscure the interpretation of adverse events; concomitant therapy with IL-2, interferon or other non-study anti-melanoma immunotherapy regimens or other investigational therapies, or chronic use of systemic corticosteroids.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma - Not AvailableHLA-A*0201-Positive Patients with Previously Treated, Unresectable Stage III or IV MelanomaEUCTR2004-005059-32-HUMedarex, Inc.1,051
进行中（未招募）
不适用
A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma - Not AvailableEUCTR2004-005059-32-DEBristol-Myers Squibb International Corporation750
进行中（未招募）
1 期
A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma - Not AvailableHLA-A*0201-Positive Patients with Previously Treated, Unresectable Stage III or IV MelanomaEUCTR2004-005059-32-GBMedarex, Inc.750
已完成
3 期
A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic SyndromeNL-OMON52320Gilead Sciences14
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer - VENICEPatients with metastatic androgen-independent prostate cancerEUCTR2006-004756-20-GBsanofi-aventis recherche & développement1,200